Diabetic macular edema (DME) is a type of eye condition in which the blood vessels in the eye get badly affected. As a result of this medical condition, fluid can leak from the blood vessels, and it flows towards the middle of the retina. The retina is a thin layer of tissue that borders the interior of the eye’s rear wall. As a result, you may lose some or all of your site if it’s not addressed.
The National Eye Institute reports that the DME generally affects around 7.5 lakhs of the US population. According to the research, up to 10% of patients with diabetes may suffer from the problem. In terms of global statistics, the International Diabetes Federation (IDF) estimates that diabetic macular edema affects more than 28 million people globally.
Report Key Takeaways
Some of the recommended treatments for DME:
Laser light is used in this treatment to destroy the leaking blood vessels in the eyes. This type of laser therapy usually does not cause any discomfort. For such kinds of treatment, it may leave persistent blind patches. However, it also aids in slowing or halting the formation of new blood vessels, which could further impair vision. It helps save the remaining vision, and it may even assist in improving it marginally.
In this treatment, injections of steroids into the eye are used over a certain period to reduce the DME. Steroids may also be used when a person cannot tolerate numerous injections. However, this treatment may increase the risk of cataracts and increased intraocular pressure in the long run.
If the vitreous is dragging on the macula, your doctor is most likely to recommend undergoing surgery. In this example, the macula is restored to its natural form through vitrectomy.
Some of the Drugs recommended for DME:
- KSI-301: Kodiak Sciences
- RZ402: Rezolute
- THR-687: Oxurion
- UBX 1325: Ascentage Pharma
- APX3330: Ocuphire Pharma
Recent Developments related to Diabetic Macular Edema
- Oxurion NV, a leading biopharmaceutical company developing next-generation standard-of-care ophthalmic treatments, announced significant findings from Part A of its Phase 2 study of THR-687, an integrin antagonist, for treating diabetic macular edema.
- Roche Canada officially announced that they had received approval from Health Canada for VABYSMO®, which will be used to treat diabetic macular edema. The DME has emerged as one of the primary causes of vision loss in the Canadian population.
Major Players Working on Diabetic Macular Edema
Some leading companies dealing with the research and development activities related to the diabetic macular edema industry include Novartis, Momenta Pharmaceuticals, Adverum Biotechnologies, Inc., Roche, and Kodiak Sciences Inc.
These industry-dominant companies are forming strategic alliances to conduct higher R&D activities to identify significant risks and possible solutions that could play a big role in managing DME.
Key Reasons to Purchase This Report
- The pipeline insights offer a broader outlook of major treatments for DME which covers the entire product development cycle, covering all product types, clinical and non-clinical stages, and product development stages.
- The pipeline’s assessment part sheds light on the DME commercial assessment as well as a clinical assessment of the pipeline drugs in development.
- The pipeline insight features detailed information on acquisitions, collaborations, partnerships, and licensing, along with a special emphasis on the evaluation of new DME treatments.